Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01331109 · ClinicalTrials.gov registry record · Phase 2
Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia
A Phase 2 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT01331109 is a Phase 2 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 57 participants.
The verdict
NCT01331109, a Phase 2 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and efficacy of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
Interventions
- DRUG Milnacipran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01331109
The ClinicalTrials.gov registry entry for NCT01331109 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Milnacipran is the first listed.
NCT01331109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01331109 about?
NCT01331109 is a clinical study titled "Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia". The purpose of this study is to evaluate the long-term safety and efficacy of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
What is the current status of trial NCT01331109?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2011-04. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01331109?
The interventions under investigation include: Milnacipran (DRUG).
Who is sponsoring clinical trial NCT01331109?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.